Mavenclad (cladribine) — the complete 2026 guide: short oral course, long-term MS control, and access in Serbia

July 2, 2026

Mavenclad (cladribine) is a uniquely "induction-style" MS therapy — patients take tablets on only ~20 days in total over 2 years, then enjoy a long drug-free interval while the drug keeps working. A detailed guide: mechanism, CLARITY and CLARITY-EXT data, safety, pregnancy, RFZO and practical steps.

What is Mavenclad

I keep returning to this subject because a useful answer should be precise without losing sight of everyday life. Mavenclad is the brand name for cladribine in tablet form — a synthetic purine analogue that selectively depletes B lymphocytes and memory T lymphocytes, the cells that drive the autoimmune attack in multiple sclerosis. Developed by Merck KGaA, approved by the EMA in August 2017 and by the FDA in March 2019 ([Merck press 2017](https://www.emdgroup.com/en/news/mavenclad-approval-eu-22-08-2017.html); [EMA EPAR — Mavenclad](https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad)). What makes it unique: this is the first and still only oral "induction" therapy for MS — patients take tablets only on a handful of days each year for two years, and then at least 2 years with no therapy at all, while the drug continues to act on the immune system.

How it works

Cladribine is an adenosine analogue that enters lymphocytes via nucleoside transporters. Inside the cell, the enzyme deoxycytidine kinase (DCK) phosphorylates it into its active form, and cells with a high DCK / 5'-nucleotidase (5'-NT) ratio — primarily B lymphocytes and memory T lymphocytes — accumulate this active form, incorporate it into DNA, and trigger programmed cell death (apoptosis). Other immune cells (neutrophils, monocytes, bone marrow) have an unfavourable DCK/5'-NT ratio and are largely spared ([Leist TP, Weissert R. Clin Neuropharmacol 2011](https://journals.lww.com/clinicalneuropharm/Abstract/2011/01000/Cladribine_A_Review.5.aspx); [Giovannoni G. Neurotherapeutics 2017](https://link.springer.com/article/10.1007/s13311-017-0573-4)).

The result is a "reset" of the autoreactive immune system: after the two short courses, the B-cell population is deeply reduced and then slowly repopulates from stem cells — but without the prior autoimmune memory. That is how Mavenclad delivers a durable effect with only ~20 dosing days over 2 years.

Who it is approved for

- Highly active relapsing-remitting MS (RRMS) in adults — patients with ≥1 relapse in the prior year and MRI signs of activity, or an inadequate response to another DMT.

- Active secondary progressive MS (SPMS) — in the EU; the FDA label is narrower.

- NOT approved for primary progressive MS (PPMS) — for that indication only Ocrevus is approved.

Dosing schedule — what treatment actually looks like

The total cumulative dose is 3.5 mg/kg of body weight, split into two annual courses. Tablets are 10 mg, and the number is set by weight.

Year 1

- First cycle: 4–5 consecutive dosing days (days 1–5, month 1).

- Second cycle: 4–5 consecutive dosing days, a month later (days 1–5, month 2).

Year 2

- Same schedule — two cycles of 4–5 days, one month apart, starting 12 months after the first day of year 1.

After year 2

No further dosing is required for at least 2 years (years 3 and 4). If disease activity returns after year 4, the neurologist decides whether to re-treat with cladribine or switch DMTs. A cumulative dose above 3.5 mg/kg over 4 years is not recommended because of the risk of deep lymphopenia and malignancy.

What the pivotal trials showed

CLARITY (RRMS)

A 96-week phase 3 trial of 1,326 patients comparing Mavenclad with placebo ([Giovannoni G et al. NEJM 2010 — CLARITY](https://www.nejm.org/doi/full/10.1056/NEJMoa0902533)):

- 57.6% fewer relapses per year (ARR 0.14 vs 0.33 on placebo).

- ~80% fewer T1 Gd+ MRI lesions and 74% fewer active T2 lesions.

- 33% lower risk of confirmed disability progression at 3 months.

- NEDA in year 2 was significantly more common in the Mavenclad arm.

CLARITY-EXT and ORACLE-MS

The CLARITY-EXT extension ([Giovannoni G et al. Mult Scler J 2018](https://journals.sagepub.com/doi/10.1177/1352458517727603)) showed the benefit lasts 3–4 years after the 2-year course ends, with no maintenance dosing. ORACLE-MS showed cladribine cuts the risk of conversion from CIS (clinically isolated syndrome) to confirmed MS by 67%.

MAGNIFY-MS and real-world evidence

MAGNIFY-MS (still ongoing, with first results 2023–2025) and registry series from Germany, Italy and the UK confirm real-world outcomes match CLARITY: >60% of patients remain relapse-free in the first 5 years, with stable disability ([Sørensen PS et al. Mult Scler J 2023](https://journals.sagepub.com/doi/10.1177/13524585231156944); [Möhn N et al. Ther Adv Neurol Disord 2024](https://journals.sagepub.com/doi/10.1177/17562864231221332)).

Safety — what to know

Most common adverse events

- Transient lymphopenia — the hallmark effect. The nadir occurs around month 2–3 after each course, then counts gradually recover.

- Herpes zoster (shingles) — increased rate; VZV vaccination is recommended at least 4–6 weeks before the first dose if the patient has not had chickenpox.

- Headache, nausea, fatigue during dosing days.

- Upper respiratory infections — mild to moderate.

Serious but rare risks

- Serious infections: patients with lymphocytes <500/μL have higher risk and the next course must be deferred until counts recover. HBV, HIV, and TB screening is mandatory before the first dose.

- Malignancy: early pre-2018 data raised concern, but the integrated 10-year analysis shows rates are not significantly higher than in the general MS population ([Cook S et al. Mult Scler Relat Disord 2019](https://www.msard-journal.com/article/S2211-0348(19)30184-8/fulltext)). Skin and gynaecological screening before and during therapy are still recommended.

- PML: no cases in CLARITY or in 10+ years of MS post-marketing surveillance.

- Hepatotoxicity: rare; liver tests are checked before and after each course.

Pregnancy and breastfeeding

Cladribine is contraindicated during pregnancy. Official guidance requires contraception during dosing and for 6 months after the last dose — for both women and men. After that interval pregnancy is considered safe because the drug is no longer in the body and the patient's immune system has already recovered. This is a real advantage over anti-CD20 drugs that require prolonged contraception or over S1P modulators.

Breastfeeding is not recommended during dosing and for 1 week afterwards.

Pregnancy registries (Merck's PRIM registry) so far have not shown an increased rate of malformations in babies conceived after the 6-month window has passed.

Mavenclad in Serbia — where it stands in 2026

Cladribine (Mavenclad) is on RFZO Lista C and 100% reimbursed by public insurance for patients with highly active relapsing-remitting MS who meet RFZO criteria ([RFZO Lista lekova](https://rfzo.rs/index.php/davalciusluga/lekovi-info/lekovi-lista)). It is prescribed through the MS-centre committee: KCS Belgrade, Niš Neurology Clinic, KC Vojvodine Novi Sad, KC Kragujevac, and the Military Medical Academy (VMA) Belgrade. The practical path:

1. The MS-centre neurologist evaluates disease activity (relapses, MRI, EDSS).

2. Documentation goes to the RFZO committee — if criteria are met (e.g. failure or intolerance of another DMT, or highly active disease), therapy is approved.

3. Before the first dose: full blood count, liver tests, HBV/HIV/TB screening, gynaecological exam (women), dermatology review, brain MRI, and vaccinations as needed.

4. Tablets are dispensed at the MS-centre pharmacy and taken at home according to the schedule.

5. Monitoring: CBC at 2 and 6 months and before each subsequent course; MRI once a year.

Mavenclad compared with other DMTs

- vs Ocrevus / Kesimpta (anti-CD20): comparable efficacy in highly active RRMS, but with dramatically fewer treatment days. Anti-CD20 drugs need continuous dosing (infusion every 6 months or monthly injection); Mavenclad is "treat and forget" — 20 days over 2 years, then a 2+-year break.

- vs natalizumab (Tysabri): Mavenclad has no PML risk and no rebound on stopping; natalizumab acts faster but needs monthly infusions and JCV monitoring.

- vs fingolimod / siponimod (Gilenya / Mayzent): Mavenclad does not require the cardiac, eye and CBC monitoring of S1P modulators and is more compatible with planned pregnancy.

- vs autologous HSCT (stem-cell transplant): Mavenclad is far safer and less invasive, but HSCT can yield even deeper and more durable remission in highly active cases.

Practical tips for patients on Mavenclad

- Vaccinations: complete before the first dose (VZV, HBV, pneumococcus, flu, COVID-19). No live vaccines during therapy or for 4–6 weeks after.

- Blood counts: before each course and at 2 and 6 months afterwards. The next course is held if lymphocytes are <800/μL.

- Symptom diary: record fevers, rashes, shingles, or signs of infection.

- Contraception: women and men must use reliable contraception during each course and for 6 months after the last dose of that year. Women on oral contraceptives should add a barrier method for 4 weeks from the start of each course.

- Travel: store tablets at room temperature and avoid skin contact with others (always wash hands after handling).

- MRI: once a year to track efficacy and exclude the rare possibility of PML.

In 2026, Mavenclad (cladribine) is confirmed as a unique, effective and practical option for highly active relapsing-remitting MS — only ~20 dosing days over 2 years and a long drug-free interval, with efficacy approaching that of anti-CD20 drugs. In Serbia it is 100% reimbursed via RFZO Lista C at accredited MS centres. For patients who want to avoid ongoing hospital visits, are planning pregnancy over the medium term, or prefer an "induction-style immune reset", Mavenclad remains one of the most attractive DMT options.

Sources

Giovannoni G et al. Cladribine Tablets for Multiple Sclerosis (CLARITY). NEJM 2010: https://www.nejm.org/doi/full/10.1056/NEJMoa0902533. Giovannoni G et al. CLARITY-EXT 4-year data. Mult Scler J 2018. Cook S et al. Safety of cladribine tablets in MS — integrated analysis. Mult Scler Relat Disord 2019: https://www.msard-journal.com/article/S2211-0348(19)30184-8/fulltext. Sørensen PS et al. Real-world experience with cladribine tablets. Mult Scler J 2023. Möhn N et al. Long-term effectiveness of cladribine. Ther Adv Neurol Disord 2024. EMA EPAR — Mavenclad: https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad. RFZO Lista lekova: https://rfzo.rs/index.php/davalciusluga/lekovi-info/lekovi-lista. This article is educational, does not constitute medical advice, and must not be used as the basis for changing therapy without consulting your MS-centre neurologist.